MetaCap

Dare Bioscience (DARE) vs Moleculin Biotech (MBRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Moleculin Biotech is the larger company by market cap ($8.2 million vs $8.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DARE-48.43%MBRX+1663.50%
+2114%+981%-151%
Oct 7, 20261 yearNov 20, 2026
DARE-47.32%MBRX+1651.13%
+1964%+911%-143%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DARE versus MBRX key metrics
MetricDAREMBRX
Share price$0.4074$7.74
Market cap$8.01M$8.22M
1-day change-9.87%-2.40%
YTD return-78.89%—
1-year return-75.75%—
5-year return-98.10%—
P/E ratio (TTM)—0.04
EPS (TTM)$-0.61$179.60
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.03M$0
Revenue growth (YoY)+10429.36%—
Net income (latest FY)$-13.40M$-33.56M
Gross margin71.29%—
Operating margin-1315.51%—
Net margin-1300.66%—
52-week high$3.78$202.50
52-week low$0.406$3.22
Distance from 52-week high-89.22%-96.18%
Analyst consensusnonestrong_buy
Avg. price target upside+1944.67%+55.04%
Average volume242.39K44.66K
Shares outstanding19.67M1.06M
Employees2117
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Dare Bioscience

DARE stock →

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Moleculin Biotech

MBRX stock →

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

DARE vs MBRX FAQ

Which is bigger, Dare Bioscience or Moleculin Biotech?

Moleculin Biotech (MBRX) is larger, with a market capitalization of $8.22M compared with $8.01M for Dare Bioscience (DARE).

Are Dare Bioscience and Moleculin Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons